Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejphar.2021.173988 http://scihub22266oqcxt.onion/10.1016/j.ejphar.2021.173988 33667455!7923868!33667455     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33667455&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Pharmacol 2021 ; 898 (ä): 173988 Nephropedia Template TP {{tp|p=33667455|t=2021. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19 |pdf=|usr=}}{{33667455}} gab.com Text Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19 JO: Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33667455 #FOAvip There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This article will review the reasons to consider valproic acid as a potential therapeutic to prevent severe COVID-19. Valproic acid could reduce angiotensin-converting enzyme 2 and transmembrane serine protease 2 expression, required for SARS-CoV-2 viral entry, and modulate the immune cellular and cytokine response to infection, thereby reducing end-organ damage. The combined anti-thrombotic, anti-platelet, and anti-inflammatory effects of valproic acid suggest it could be a promising therapeutic target for COVID-19. Twit Text FOAVip Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19 ????Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33667455 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33667455 #FOAvip English Wikipedia <ref>{{Cite pmid|33667455}}</ref> Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19 #MMPMID33667455 Pitt B; Sutton NR; Wang Z; Goonewardena SN; Holinstat M Eur J Pharmacol 2021[May]; 898 (ä): 173988 PMID33667455show ga There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This article will review the reasons to consider valproic acid as a potential therapeutic to prevent severe COVID-19. Valproic acid could reduce angiotensin-converting enzyme 2 and transmembrane serine protease 2 expression, required for SARS-CoV-2 viral entry, and modulate the immune cellular and cytokine response to infection, thereby reducing end-organ damage. The combined anti-thrombotic, anti-platelet, and anti-inflammatory effects of valproic acid suggest it could be a promising therapeutic target for COVID-19. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Animals[MESH] |Anti-Inflammatory Agents/*therapeutic use[MESH] |COVID-19/prevention & control[MESH] |Drug Repositioning[MESH] |Fibrinolytic Agents/*therapeutic use[MESH] |Histone Deacetylase Inhibitors/*therapeutic use[MESH] |Humans[MESH] |Platelet Aggregation Inhibitors/*therapeutic use[MESH]Potential repurposing of the HDAC inhibitor valproic acid for patients(epmc).pdf DeepDyve Pubget Overpricing